Office of the Provost

Dean of the School of Pharmacy 2008

Dear Colleagues:

I am delighted to announce that Thomas Baillie has accepted our offer to become the next dean of the University of Washington School of Pharmacy.

Baillie has had a distinguished academic career and also has worked in leadership positions in private industry. His appointment, effective October 1, 2008, is subject to approval of the UW Board of Regents.

Tom Baillie will be returning to the UW to lead the school where he spent so many productive and satisfying years on the faculty. The combination of his experience and familiarity with the UW and his frontline experience in industry makes him a very attractive candidate–uniquely qualified–to lead the School of Pharmacy. We’re very excited by his return.

Baillie has been at Merck & Co., Inc., a global pharmaceutical company, since 1994. He was executive director of preclinical drug metabolism from 1994 to 1996, vice president of drug metabolism from 1996 to 2007, and most recently was vice president and global head of drug metabolism and pharmacokinetics. Baillie’s division was responsible for evaluating the way potential drugs are absorbed and metabolized by the human body Baillie’s academic career began at the University of London, in 1975, where he was a lecturer in analytical chemistry in the Department of Clinical Pharmacology. In 1978 he joined the University of California – San Francisco., and in 1981, he became a member of the pharmacy faculty at the UW, where he stayed until joining Merck in 1994.

Baillie served as a science advisor to the Food and Drug Administration’s regional San Francisco office in 1980-81 and as a special reviewer of the metallobiochemistry study section of the National Institutes of Health in 1985. He was co-recipient of the “Best Paper Award” for an article published in the journal of the American Society for Pharmacology and Experimental Therapeutics in 1986, 1993 and 2001.

At Merck, Baillie was head of a division of 350 employees and reported to the senior vice president for worldwide preclinical development.

Baillie has a B.S in chemistry (1970), Ph.D. in organic chemistry (1973, and D.Sc. in chemistry (1992) from the University of Glasgow. He also has an M.S. in biochemistry (1978) from the University of London.

The University of Washington School of Pharmacy is recognized nationally as an innovative leader in pharmacy education, scholarship, and research. Its students are among the best and the brightest and continue to be an influential force long after graduation. The school ranks fifth among pharmacy schools in the country, according to annual rankings of graduate and professional programs provided by U.S. News & World Report.

Please join me in welcoming Dr. Thomas Baillie as the next dean of this wonderful school!

Sincerely,

Phyllis M. Wise
Provost and Executive Vice President
University of Washington